Chica­go-area biotech sends 2nd drug to In­di­a's reg­u­la­tors; Pen­ny stock play­er spins out PhI­II can­cer can­di­date in­to new com­pa­ny

Phar­mazz is on its way to In­dia’s drug reg­u­la­tor for the sec­ond time as its in­ves­ti­ga­tion­al treat­ment passed muster in a Phase III study in pa­tients with acute is­chemic stroke.

The Chica­go sub­urbs-based biotech said its drug so­vateltide led to bet­ter im­prove­ment than place­bo on cer­tain mea­sure­ments of neu­ro­log­i­cal out­comes.

So­vateltide led an im­prove­ment of ≥2 points on mRS and an in­crease of ≥6 points on NIHSS at day 90 in the tri­al of 158 adults in In­dia. The mod­i­fied Rankin scale looks at the de­gree of de­pen­dence in the dai­ly ac­tiv­i­ties of peo­ple post-stroke event, and the NIH stroke scale mea­sures the stroke-re­lat­ed neu­ro­log­ic deficit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER